Aptevo Therapeutics (APVO) Competitors $3.10 +0.20 (+6.90%) Closing price 04:00 PM EasternExtended Trading$3.02 -0.08 (-2.58%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock APVO vs. APRE, GTBP, DWTX, KPRX, AEON, LSB, TCRT, SNPX, CHRO, and TSBXShould you be buying Aptevo Therapeutics stock or one of its competitors? The main competitors of Aptevo Therapeutics include Aprea Therapeutics (APRE), GT Biopharma (GTBP), Dogwood Therapeutics (DWTX), Kiora Pharmaceuticals (KPRX), AEON Biopharma (AEON), LakeShore Biopharma (LSB), Alaunos Therapeutics (TCRT), Synaptogenix (SNPX), Chromocell Therapeutics (CHRO), and Turnstone Biologics (TSBX). These companies are all part of the "pharmaceutical products" industry. Aptevo Therapeutics vs. Its Competitors Aprea Therapeutics GT Biopharma Dogwood Therapeutics Kiora Pharmaceuticals AEON Biopharma LakeShore Biopharma Alaunos Therapeutics Synaptogenix Chromocell Therapeutics Turnstone Biologics Aptevo Therapeutics (NASDAQ:APVO) and Aprea Therapeutics (NASDAQ:APRE) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations. Is APVO or APRE more profitable? Aptevo Therapeutics has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -1,095.02%. Aprea Therapeutics' return on equity of -68.39% beat Aptevo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aptevo TherapeuticsN/A -779.42% -175.59% Aprea Therapeutics -1,095.02%-68.39%-55.74% Do institutionals & insiders believe in APVO or APRE? 8.1% of Aptevo Therapeutics shares are held by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are held by institutional investors. 0.1% of Aptevo Therapeutics shares are held by insiders. Comparatively, 13.6% of Aprea Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has better earnings and valuation, APVO or APRE? Aprea Therapeutics has lower revenue, but higher earnings than Aptevo Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAptevo Therapeutics$3.11M0.76-$24.13MN/AN/AAprea Therapeutics$1.50M6.64-$12.96M-$2.37-0.76 Does the media prefer APVO or APRE? In the previous week, Aptevo Therapeutics had 2 more articles in the media than Aprea Therapeutics. MarketBeat recorded 2 mentions for Aptevo Therapeutics and 0 mentions for Aprea Therapeutics. Aptevo Therapeutics' average media sentiment score of 0.00 equaled Aprea Therapeutics'average media sentiment score. Company Overall Sentiment Aptevo Therapeutics Neutral Aprea Therapeutics Neutral Do analysts rate APVO or APRE? Aptevo Therapeutics presently has a consensus price target of $219,040.00, suggesting a potential upside of 7,065,706.45%. Aprea Therapeutics has a consensus price target of $15.50, suggesting a potential upside of 761.11%. Given Aptevo Therapeutics' higher probable upside, research analysts clearly believe Aptevo Therapeutics is more favorable than Aprea Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptevo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Aprea Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, APVO or APRE? Aptevo Therapeutics has a beta of 5.58, indicating that its share price is 458% more volatile than the S&P 500. Comparatively, Aprea Therapeutics has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. SummaryAprea Therapeutics beats Aptevo Therapeutics on 7 of the 12 factors compared between the two stocks. Get Aptevo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APVO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding APVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APVO vs. The Competition Export to ExcelMetricAptevo TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.19M$2.88B$5.47B$8.95BDividend YieldN/A2.46%5.25%4.06%P/E RatioN/A20.8027.0020.10Price / Sales0.76286.98435.75120.29Price / CashN/A41.1936.8257.86Price / Book0.057.487.985.56Net Income-$24.13M-$55.04M$3.16B$248.40M7 Day Performance5.08%5.44%3.69%6.04%1 Month Performance-37.37%2.38%2.91%7.69%1 Year Performance-99.96%5.53%34.30%20.97% Aptevo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APVOAptevo Therapeutics2.0988 of 5 stars$3.10+6.9%$219,040.00+7,065,706.5%-100.0%$2.19M$3.11M0.0050APREAprea Therapeutics2.5035 of 5 stars$1.69+0.9%$15.50+817.2%-55.4%$9.27M$1.50M-0.717GTBPGT Biopharma1.3975 of 5 stars$3.58+1.1%$11.00+207.3%-24.7%$9.16MN/A-0.638DWTXDogwood Therapeutics1.1519 of 5 stars$4.77+1.3%$10.00+109.6%N/A$9MN/A-0.265Positive NewsKPRXKiora Pharmaceuticals2.2638 of 5 stars$2.88-0.7%$10.00+247.2%-38.8%$8.83M$16.02M-0.9910Positive NewsAEONAEON Biopharma3.3459 of 5 stars$0.76+0.1%$360.00+47,268.4%-98.9%$8.59MN/A4.225LSBLakeShore Biopharma0.3436 of 5 stars$1.02+11.0%N/AN/A$8.55M$80.82M0.00773News CoveragePositive NewsGap UpHigh Trading VolumeTCRTAlaunos Therapeutics0.4887 of 5 stars$4.85-5.5%N/A-21.3%$8.41M$10K-1.9140SNPXSynaptogenix1.1525 of 5 stars$7.85+29.8%$14.00+78.3%+106.8%$8.40MN/A-0.784High Trading VolumeCHROChromocell TherapeuticsN/A$1.26-6.7%N/A-89.1%$8.31MN/A-1.024Gap UpTSBXTurnstone Biologics1.5663 of 5 stars$0.36+1.8%$0.45+25.3%-83.7%$8.16M$19.31M-0.1382High Trading Volume Related Companies and Tools Related Companies APRE Alternatives GTBP Alternatives DWTX Alternatives KPRX Alternatives AEON Alternatives LSB Alternatives TCRT Alternatives SNPX Alternatives CHRO Alternatives TSBX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APVO) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | Sponsored$3,200 from your phone?No charts. No crypto. No stock picking. With just a regular brokerage app and Jeff Clark’s “Crossfire” meth...TradeSmith | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptevo Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptevo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free APVO Stock Alerts